What treatments are available for diabetic retinopathy in the UK? 

In the United Kingdom, treatment for diabetic retinopathy is specifically reserved for advanced stages where there is a clear and present danger to a patient’s sight. The NHS and the National Institute for Health and Care Excellence (NICE) provide a tiered treatment framework that addresses two primary complications: proliferative retinopathy (the growth of new vessels) and diabetic macular oedema (swelling of the central vision). While early “background” retinopathy is managed through systemic health control, advanced cases are treated using localized interventions such as lasers, injections, or surgery. The goal of these treatments is primarily to stabilize the eye and prevent further vision loss, although some modern therapies can also lead to an improvement in visual clarity. 

What We’ll Discuss in This Article 

• The use of laser treatment for proliferative disease and maculopathy. 

• The role of anti-VEGF injections in reducing retinal swelling. 

• When vitreoretinal surgery (vitrectomy) becomes a clinical necessity. 

• The use of long-acting steroid implants for chronic macular oedema. 

• New oral medications (fenofibrate) for slowing disease progression. 

• Emergency treatment pathways for sudden visual complications. 

Laser Treatment (Photocoagulation) 

Laser treatment remains a cornerstone of diabetic eye care in the UK. It involves focusing an intense beam of light onto the retina to create tiny burns that help stabilize the condition. There are two primary types of laser therapy used depending on the patient’s needs: 

1. Pan-Retinal Photocoagulation (PRP): Used for proliferative retinopathy (R3A). The laser is applied to the peripheral retina to reduce its demand for oxygen, which causes abnormal new blood vessels to shrink and disappear. This “peripheral scatter” prevents major bleeds and retinal detachment. 

2. Macular Laser: Used for certain cases of maculopathy. The specialist applies gentle laser burns directly to leaking microaneurysms or in a grid pattern to “dry up” fluid near the central vision. 

According to NHS Inform, laser treatment is highly effective; when applied at the correct stage for proliferative disease, it can prevent severe sight loss in over 90% of cases. 

Anti-VEGF Injections 

Injections of anti-vascular endothelial growth factor (anti-VEGF) medications are the gold standard for treating diabetic macular oedema (DMO). These drugs block the chemical signal (VEGF) that causes blood vessels to leak and grow abnormally. Common medications used in the NHS include Aflibercept (Eylea), Ranibizumab (Lucentis), and more recently, Faricimab (Vabysmo). 

The treatment typically involves a “loading phase” of monthly injections for several months, followed by a maintenance phase where the interval between injections is gradually increased. NICE guidelines (NG242) now recommend considering these injections for patients with central retinal swelling and visual impairment, even if the retinal thickness is less than 400 micrometres, ensuring earlier access to care. 

Vitreoretinal Surgery (Vitrectomy) 

Surgery is usually reserved for the most advanced cases of proliferative retinopathy where laser treatment is no longer possible or has not been fully effective. The operation, known as a vitrectomy, involves making tiny incisions in the eye to remove the vitreous gel. 

This surgery is clinically necessary if: 

• A large amount of blood has collected in the eye (vitreous haemorrhage) and has not cleared on its own. 

• Extensive scar tissue is pulling the retina away from the back of the eye (tractional retinal detachment). 

During the procedure, the surgeon can also apply “endolaser” treatment directly to the retina and remove any membranes or scar tissue. NHS Foundation Trust leaflets explain that while the eye may be red and sensitive for several weeks after surgery, it is a vital intervention for restoring clarity in severely affected eyes. 

Intravitreal Steroid Implants 

For patients who do not respond well to anti-VEGF injections, or for whom injections are unsuitable, the NHS offers long-acting steroid implants. These are injected into the eye in a similar way to anti-VEGF drugs but release medication slowly over a much longer period. 

• Ozurdex (Dexamethasone): A biodegradable implant that lasts for up to six months. 

• Iluvien (Fluocinolone acetonide): A non-erodible tiny tube that can release medication for up to three years. 

These steroids are particularly useful for tackling the inflammatory component of chronic macular oedema. However, they carry a higher risk of increasing eye pressure (glaucoma) and causing cataracts, so patients receiving these implants are monitored very closely by their specialist. 

New and Emerging Treatments 

The landscape of diabetic eye care in the UK is constantly evolving. As of 2024 and 2025, new recommendations have been introduced to help prevent the need for intensive eye treatments: 

• Fenofibrate: NICE now suggests that ophthalmologists consider prescribing fenofibrate (an oral tablet) for people with non-proliferative retinopathy and Type 2 diabetes. Evidence suggests it can help slow the progression of the disease, potentially reducing the need for future lasers or injections. 

• Biosimilars: To ensure cost-effective care, the NHS has introduced biosimilar versions of drugs like Ranibizumab. These work in the same way as the original “branded” drugs but allow the NHS to treat more patients within the same budget. 

Treatment Type	Primary Use Case	Main Goal
Peripheral Laser (PRP)	Proliferative Retinopathy	Shrink new vessels & prevent bleeds
Anti-VEGF Injections	Macular Oedema (Swelling)	Reduce fluid & improve clarity
Steroid Implants	Chronic / Persistent Swelling	Long-term inflammation control
Vitrectomy Surgery	Bleeding or Scar Tissue	Remove blood & reattach retina
Fenofibrate (Oral)	Non-proliferative disease	Slow disease progression

Conclusion 

Treatments for diabetic retinopathy in the UK range from localized laser therapy and anti-VEGF injections to advanced vitreoretinal surgery. While the NHS focuses on stabilizing the eye to prevent sight loss, many modern treatments can also help improve vision that has already been affected by swelling. The choice of treatment depends on the specific grade of retinopathy found during screening and the presence of macular involvement. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot 

This article provides a comprehensive overview of the diabetic retinopathy treatment landscape in the UK, incorporating 2024 and 2025 NICE (NG242) updates. The content is written to meet UK medical standards and has been reviewed by the Medical Content Team to ensure alignment with NHS England and Royal College of Ophthalmologists protocols. Our goal is to help patients understand the clinical options available to protect their sight.